Teva Pharmaceutical Industries Ltd has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs.

Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a ...

Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholesterol to settle price-fixing charges from the US Department of Justice, the agency ...

FTC opens investigation into Teva, escalating patent fight with pharma industry Democrats have accused drug companies of “junk patent listings,” arguing that the industry is blocking generic ...

Teva Pharmaceutical Industries Limited’s share was trading at $17.09 as of June 24th. TEVA’s trailing and forward P/E ratios were 872.00 and 6.53, respectively, according to Yahoo Finance.

Teva Pharmaceuticals agreed Thursday to pay New York $523 million to settle claims stemming from the company’s role in the opioids crisis. It’s the largest settlement New York has reached with ...